Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2716 to 2730 of 9071 results

  1. Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

  2. Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)

    Summary of the evidence on delafloxacin for community-acquired pneumonia in adults

  3. Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)

    Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults

  4. Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adults (ES40)

    Summary of the evidence on eravacycline for complicated intra-abdominal infections in adults

  5. Desflurane for maintenance of anaesthesia (ES41)

    Summary of the evidence on desflurane for maintenance of anaesthesia

  6. Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)

    Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders

  7. Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)

    Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

  8. Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

    Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making

  9. Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

    Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

  10. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

    Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

  11. Digital ulcers: sildenafil (ESUOM42)

    Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making

  12. Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

    Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

  13. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  14. Melatonin for treating sleep disorders in adults who are blind (ES38)

    Summary of the evidence on melatonin for treating sleep disorders in adults who are blind

  15. Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)

    Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam